Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Melanoma
Related studies linked through entity extraction aliases.
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
- Status
- TERMINATED
- Phase
- PHASE3
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab
- Status
- COMPLETED
- Phase
- PHASE2
Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma
- Status
- UNKNOWN
- Phase
- PHASE2
OH2 Injection in Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma
- Status
- UNKNOWN
- Phase
- PHASE1
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
- Status
- RECRUITING
- Phase
- N/A
Atypical MOLes and Melanoma Early Detection Study (MoleMed)
- Status
- UNKNOWN
- Phase
- NA
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Hydrochlorothiazide and Risk of Skin Cancer
- Status
- COMPLETED
- Phase
- N/A
National Cancer Institute "Cancer Moonshot Biobank"
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2